Gut dysbiosis in Alzheimer's disease reduces butyrate-producing bacteria (Faecalibacterium prausnitzii, Roseburia intestinalis), causing systemic butyrate deficiency. Butyrate normally acts as an endogenous histone deacetylase (HDAC) inhibitor; decreased butyrate allows HDAC2 to suppress histone acetylation at promoters of anti-inflammatory genes in microglia, impairing their ability to phagocytose and clear amyloid-beta plaques. This HDAC2-mediated epigenetic silencing reduces expression of genes encoding phagocytic receptors (TREM2, CR3) and lysosomal enzymes, creating a feed-forward loop where accumulated amyloid further disrupts gut barrier integrity and exacerbates dysbiosis.
...
Gut dysbiosis in Alzheimer's disease reduces butyrate-producing bacteria (Faecalibacterium prausnitzii, Roseburia intestinalis), causing systemic butyrate deficiency. Butyrate normally acts as an endogenous histone deacetylase (HDAC) inhibitor; decreased butyrate allows HDAC2 to suppress histone acetylation at promoters of anti-inflammatory genes in microglia, impairing their ability to phagocytose and clear amyloid-beta plaques. This HDAC2-mediated epigenetic silencing reduces expression of genes encoding phagocytic receptors (TREM2, CR3) and lysosomal enzymes, creating a feed-forward loop where accumulated amyloid further disrupts gut barrier integrity and exacerbates dysbiosis. Oral supplementation with butyrate or butyrate-producing bacterial consortia would restore microglial epigenetic regulation and enhance amyloid clearance.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["HDAC2 Activity Histone Deacetylase"]
B["Microglial Epigenetic Regulation"]
C["Phagocytosis Gene Expression"]
D["Microglial Amyloid Clearance Capacity"]
E["HDAC-Dependent Epigenetic Dysregulation"]
F["HDAC2 as Microglial Reprogramming Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Median TPM across 13 brain regions for HDAC2 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations5 with PMID5 mediumValidation: 0%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-10 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Based on the provided literature, I'll generate novel therapeutic hypotheses targeting the gut-brain axis for Alzheimer's disease. The evidence shows clear mechanistic connections between gut microbiota dysbiosis, neuroinflammation, and AD pathogenesis that can be therapeutically exploited.
HYPOTHESIS 1: Selective Microglial Reprogramming via Engineered Probiotic Metabolites
Description: Genetically engineered probiotics producing specific short-chain fatty acids (SCFAs) like butyrate and propionate can selectively reprogram microglial activation from pro-inflammatory M1 to neuroprote
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
I'll provide a rigorous critique of each hypothesis, identifying weaknesses and providing revised confidence scores based on the available evidence.
HYPOTHESIS 1: Selective Microglial Reprogramming via Engineered Probiotic Metabolites
Critical Weaknesses:
Blood-brain barrier limitation: SCFAs have limited BBB penetrance, with most studies showing only modest CNS concentrations despite high peripheral levels
Microglial heterogeneity oversimplification: The M1/M2 paradigm is outdated - microglia exist in multiple activation states that don't fit this binary classification
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Based on my analysis of the hypotheses and the provided literature, I'll assess the practical feasibility of the surviving hypotheses that show some promise. Most of the original hypotheses face fundamental biological barriers, but I'll focus on the most viable approaches.
HYPOTHESIS 5: Gut Barrier Restoration (Revised Confidence: 0.55)
Most Promising Approach
Druggability Assessment
Highly Druggable - Multiple validated targets and existing therapeutic approaches:
Target 1: Tight junction proteins (claudin-1, occludin, ZO-1) - druggable via small molecules
*Target 2
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF adult 5xFAD mice with established amyloid pathology are given oral sodium butyrate supplementation (150 mg/kg/day) for 8 weeks, THEN hippocampal amyloid plaque burden will decrease by at least 25% compared to vehicle-treated controls, as quantified by Thioflavin-S or 11C-PiB PET imaging.
pendingconf: 0.65
Expected outcome: Hippocampal amyloid plaque burden reduced by ≥25% (Thioflavin-S stereology or 11C-PiB PET SUVR) after 8 weeks of butyrate supplementation
Falsified by: No significant difference in amyloid plaque load between butyrate and vehicle groups (p > 0.05), indicating butyrate supplementation does not reduce amyloid burden
Method: 5xFAD transgenic mice (both sexes, 4-6 months old) randomized to sodium butyrate (150 mg/kg/day via drinking water) or vehicle for 8 weeks; amyloid quantified via Thioflavin-S stereology or in vivo 11C-PiB PET at baseline and endpoint; n ≥ 12 per group
IF butyrate supplementation restores microglial phagocytic capacity, THEN butyrate-treated 5xFAD mice will show at least 2-fold increase in TREM2 and CR3 gene expression and enhanced in vivo amyloid phagocytosis rate compared to vehicle controls.
pendingconf: 0.55
Expected outcome: TREM2 and CR3 mRNA expression ≥2-fold higher; in vivo phagocytosis assay shows ≥2-fold increased amyloid internalization by microglia in butyrate-treated mice
Falsified by: TREM2/CR3 expression unchanged or decreased despite butyrate treatment, or no increase in amyloid phagocytosis rate, indicating HDAC2 is not mediating butyrate's effects on microglial gene expression
Method: Primary microglia isolated from butyrate-treated 5xFAD mice (or human post-mortem AD brains with Faecalibacterium prausnitzii quantification) for qPCR of TREM2, CR3, and cathepsin D; ex vivo phagocytosis assay with AF488-Aβ42 fibrils; HDAC2 chromatin immunoprecipitation at target promoters